C vs SGMO · P/E 16, rev $85.22B vs rev $57.8M
Citigroup Inc. (C) versus Sangamo Therapeutics Inc (SGMO) — a side-by-side from cached financials, not a winner call.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Sangamo Therapeutics Inc (SGMO) is a biotechnology company listed on NASDAQ.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
Latest reported SGMO revenue for 2024-12-31 was $57.8M. Net income was -$97.9M. Revenue was down 67.2% from 2023-12-31 to 2024-12-31. SGMO currently screens at market cap $74.6M.
C currently screens at market cap $214.73B and trailing P/E 15.5. SGMO currently screens at market cap $74.6M.
Not investment advice. Open the C and SGMO stock pages for the full models.
Not investment advice.